Related by context. All words. (Click for frequent words.) 64 Randomized Evaluation 63 prospective multicentre 63 APTIVUS 63 BCIRG 63 CHAMPION PCI 62 PRoFESS 62 Fondaparinux 62 Pertuzumab 61 Myocardial Perfusion Imaging 61 NSABP B 61 phase IIIb 61 Parathyroid Hormone 61 CIMZIA TM certolizumab pegol 61 demonstrated clinically meaningful 60 Spine Patient Outcomes 60 Tumor Response 60 Blinatumomab 60 Phase III multicenter 60 relapsed MM 60 STRIDE PD 60 dalteparin 60 Xelox 60 Degarelix 60 See CLINICAL PHARMACOLOGY 60 Cardiotoxicity 60 Protease Inhibitors 60 RE MODEL 59 neoadjuvant treatment 59 fosbretabulin 59 Randomized controlled 59 MAGE A3 ASCI 59 multicenter multinational 59 multicenter randomized controlled 59 multicentre randomized 59 Zemplar Capsules 59 fecal immunochemical test 59 Refractory Angina 59 adenoma recurrence 59 ritonavir boosted 59 Betaferon R 59 abacavir Ziagen 59 RE LY 59 RESOLUTE clinical 59 Phase IIIb clinical 59 multicenter Phase II 59 genotypic resistance 59 Shows Efficacy 59 novel oral anticoagulant 59 Phase Ib II 59 Intervention Trial 59 Percutaneous Tibial Nerve Stimulation 59 Neoadjuvant 59 darunavir r 59 AIR CF1 58 Long Term Efficacy 58 Teriparatide 58 neurologic progression 58 multicenter prospective 58 unfractionated heparin UFH 58 Dalbavancin 58 beta 1a 58 INSPIRE Trial Phase III 58 Prospective Multicenter 58 line Indolent Trial 58 YONDELIS 58 registrational Phase 58 ibandronate 58 acyclovir Lauriad R 58 Clinical Outcome 58 Prospective Randomized 58 Deforolimus 58 Raloxifene STAR 58 androgen suppression 58 randomized multicenter Phase III 58 tiuxetan 58 rFSH 58 mITT population 58 Sirolimus eluting 58 ENGAGE AF TIMI 58 Double Blind Randomized 58 Parathyroid hormone 58 Capesaris 58 Glatiramer acetate 58 CAMMS# 58 Cinacalcet 58 NSABP C 58 corifollitropin alfa 58 HDL Selective Delipidation 58 EOquin TM 58 cinacalcet 58 recurrent metastatic 58 Tarsa oral calcitonin 58 Pegylated Liposomal Doxorubicin 58 Temsirolimus 58 Phase IIb III 58 Adenoma Prevention 58 somatostatin analog 58 Schizophrenia Treatment 58 sargramostim 58 ILLUSTRATE 58 Posaconazole 58 BRIM3 58 Androgel R 58 zoledronate 58 randomized Phase IIb 57 pharmacodynamic effects 57 Carotid Revascularization Endarterectomy vs. 57 ZACTIMA 57 pain palliation 57 GISSI 57 DAPT 57 ZOLINZA 57 Multiple Ascending Dose 57 Dabigatran etexilate 57 Randomised 57 RhuDex 57 ACTIVE W 57 Intravitreal 57 CALGB 57 BRIM2 57 MVA MUC1 IL2 57 alendronate Fosamax 57 PRESEPT 57 direct thrombin inhibitors 57 ENESTnd 57 pegylated liposomal doxorubicin 57 Intervention Trial GAIT 57 Alexion Soliris 57 atazanavir ritonavir 57 tipifarnib 57 CLIRS 57 ELONVA 57 Exemestane 57 NCIC CTG 57 ASTEROID 57 NN# [001] 57 prospective nonrandomized 57 ToGA 57 HCV SPRINT 57 Prolongs Survival 57 Protease Inhibitor 57 Enzastaurin 57 Pemetrexed 57 Patency 57 Pharmacokinetics PK 57 p# biomarker 57 NSABP 57 RE LY ® 57 multicentre randomized controlled 57 Femara letrozole 57 adefovir dipivoxil 57 Tyrosine Kinase Inhibitor 57 Bosutinib 57 Aggressive Drug Evaluation 57 Simulect 57 clevidipine 57 Immunotherapeutic 57 Intervention Effectiveness 57 recurrent glioblastoma multiforme 57 Vascugel ® 57 Pazopanib 57 glucocorticoid induced osteoporosis 57 ADMIRE HF 57 PRIALT 57 BARI 2D 57 Hepatotoxicity 57 HMG CoA reductase inhibitors 57 APTIVUS r 57 LEXIVA r 57 thalidomide Thalomid 57 pharmacokinetic PK study 57 HuMax EGFr 57 confirmatory clinical 57 multicentre prospective 57 observational cohort study 57 Febuxostat 56 Alequel 56 prospective randomized controlled 56 Novel Therapeutic 56 sunitinib malate 56 neratinib 56 HF ACTION 56 strontium ranelate 56 Trandolapril 56 Toremifene 56 Velcade bortezomib 56 epoetin alpha 56 PREVENT IV 56 MEVACOR 56 pegylated interferon alfa 2b 56 Tacrolimus 56 alpha 2a 56 Pharmacodynamic 56 ENDEAVOR IV 56 oral FTY# 56 Thymosin Beta 4 56 REMINYL ® 56 vidofludimus 56 substudy 56 gemcitabine carboplatin 56 Hormone Refractory Prostate Cancer 56 Patients Receiving 56 velafermin 56 Interferon beta 1b 56 APPRAISE 56 basal bolus regimen 56 Abciximab 56 NeuroVax 56 5 Fluorouracil 56 Alequel ™ 56 randomized multicenter trial 56 ONTARGET 56 treatment naive genotype 56 Tarceva TM 56 hematological parameters 56 Hsp# Inhibitor 56 TASKi3 56 thorough QT 56 pharmacokinetics PK 56 boosted protease inhibitor 56 multicenter phase 56 Denufosol 56 carotid artery stenting CAS 56 Achieves Primary Endpoint 56 glatiramer acetate 56 Pharmacokinetic 56 zonisamide SR 56 azilsartan medoxomil 56 viral kinetics 56 Daptomycin 56 GAMMAGARD 56 cathepsin K inhibitor 56 Angiotensin Converting Enzyme 56 morphometric vertebral fractures 56 gemtuzumab ozogamicin 56 Randomized Study 56 Alkeran 56 ATV RTV 56 Antiplatelet 56 REVIVE Diabetes 56 Teriflunomide 56 analgesic efficacy 56 FOLPI 56 CLARITY TIMI 56 DEB# 56 Phase III placebo controlled 56 pertuzumab 56 Randomized Phase II 56 blinded randomized 56 PKC# 56 Platelet Inhibition 56 ABSORB trial 56 fludarabine cyclophosphamide 56 β blockers 56 adalimumab Humira 56 platelet inhibitor 56 Prevent Stroke 56 Bivalirudin 56 CIMZIA TM 56 placebo controlled clinical 56 prospective randomized multicenter 56 RECORD1 56 prospectively randomized 56 Amrubicin 56 ASSERT trial 56 randomized multicenter 56 sorafenib Nexavar 56 postmenopausal osteoporotic women 56 teriflunomide 56 visilizumab 56 Biphasic 56 Microdosing 56 Phase IIIb study 56 pimecrolimus cream 56 Cimzia TM 56 CRMD# 56 phase Ib 56 FFNS 56 Combination REOLYSIN R 56 Patients Treated With 56 Olmesartan 56 anastrazole 56 concurrent chemoradiation 56 Demonstrates Efficacy 56 dasatinib Sprycel 56 Clinical Antipsychotic Trials 56 blinded randomized placebo controlled 56 Ranolazine 56 AZILECT R 56 Sipuleucel T 56 paricalcitol 56 rituximab Rituxan 56 IMPACT DCM 56 Phase Ib Clinical Trial 56 pharmacokinetic pharmacodynamic 56 Neupogen ® 56 bortezomib Velcade 56 prospective multicenter randomized 56 Antitumor 56 AERAS-#/Crucell Ad# 55 Invasive Fungal Infections 55 multicenter randomized clinical 55 monoclonal anti 55 TOLAMBA 55 Tesmilifene 55 endothelin antagonists 55 Celecoxib 55 OvaRex MAb 55 oral rivaroxaban 55 Initiated Phase 55 peg interferon 55 BARACLUDE r 55 TAXUS ATLAS 55 docetaxel Taxotere ® 55 Gastric Cancer 55 Afatinib 55 dose escalation clinical 55 R roscovitine 55 PRT# 55 Antiarrhythmic 55 prospective multicenter 55 LUX Lung 55 ROCKET AF 55 Acute Ischemic Stroke 55 abacavir lamivudine 55 Shows Promise Against 55 BoNTA 55 VNP#M 55 CHARM Added 55 interferon gamma 1b 55 immunomodulatory agents 55 MVax 55 vastus lateralis 55 BAL# [002] 55 pharmacodynamic PD 55 oral deforolimus 55 Phase Ib clinical 55 PEGPH# 55 REMUNE R 55 prucalopride 55 Diabetic Neuropathy 55 Granulocyte Colony Stimulating Factor 55 Ovarian Cancer Screening 55 AOD# [002] 55 AIR CF2 55 Virulizin ® 55 Aflibercept 55 ACOMPLIA R 55 Current Controlled Trials 55 HCD# [002] 55 BZA CE 55 thetreatment 55 metastatic malignant 55 Bioequivalence 55 selenium supplementation 55 paclitaxel poliglumex 55 evaluating Actimmune 55 number NCT# ClinicalTrials.gov 55 orally dosed 55 Aurora Kinase 55 riociguat 55 TDF FTC 55 Interferon alfa 55 Glucosamine Chondroitin Arthritis 55 ® lenalidomide 55 ixabepilone 55 Randomized Double Blind 55 Targretin capsules 55 Randomized trials 55 preclinical efficacy 55 SUTENT ® 55 Fingolimod 55 double blinded randomized 55 anti muscarinic 55 depsipeptide 55 G#DT 55 PF # [002] 55 LANTUS ® 55 Randomized Double blind 55 antibody MAb 55 TQT 55 Peripheral Arterial 55 FRAGMIN 55 zoledronic acid Reclast 55 HORIZONS AMI 55 Pivotal Trial 55 estramustine 55 SPIRIT FIRST 55 tarenflurbil 55 intermittent dosing 55 chemoradiation therapy 55 SIMPADICO 55 atherosclerotic renal artery stenosis 55 CARE HF 55 XIENCE V Stent System 55 comparator arm 55 Therapeutic Efficacy 55 Vicriviroc 55 Thorough QT 55 Cytochrome P# 55 chimeric monoclonal antibody 55 Epirubicin 55 oral ridaforolimus 55 Factor VIIa 55 Asthma Intervention 55 alicaforsen enema 55 AIR2 Trial 55 cediranib 55 colorectal adenoma 55 CLARITY study 55 Romiplostim 55 CALGB # [002] 55 mycophenolate mofetil MMF 55 EURIDIS 55 CIMZIA ™ 55 TLK# 55 selective modulator 55 DU #b 55 #mg/#mg 55 Recurrent Glioblastoma 55 FDA defined valvulopathy 55 Phase 1a clinical 55 UPLYSO 55 #F FDG PET 55 eluting stent 55 Protelos 55 viral kinetic 55 PROSTVAC ® 55 docetaxel cisplatin 55 Quinamed 55 Androxal TM 55 Screening Trial DMIST 55 dose escalation phase 55 PEGylated interferon beta 1a 55 PYY #-# 55 Antihypertensive 55 Phase IIB 55 multicentre randomized double 55 chromium supplementation 55 chemoradiotherapy 55 Kinoid 55 Aptivus ® 55 oral anticoagulation 55 metastatic neuroendocrine tumors 55 Orazol 55 iPrEx study 55 pioglitazone hydrochloride 55 NMES 55 BARACLUDE R 55 CATIE AD 55 epoetin beta 55 prospective observational cohort 55 PSMA ADC 55 BUPHENYL R 55 Tavocept 55 humanised monoclonal antibody 54 Unstable Angina 54 CIPN 54 weekly subcutaneous injections 54 Traficet EN 54 Lp PLA 2 54 REFLEX 54 Glufosfamide 54 Allogeneic 54 Adjunctive 54 dose proportionality 54 Angiolix 54 VICTOR E1 54 Dabigatran 54 assessing T DM1 54 interferon ribavirin 54 Mycophenolate Mofetil 54 Teysuno 54 SWOG 54 CAELYX 54 sevelamer hydrochloride 54 PRECISE 54 PEG SN# 54 E1 INT TM 54 efficacy tolerability 54 adjuvant cisplatin 54 beta carotene supplementation 54 canakinumab 54 bendamustine 54 Plasmin 54 EchoCRT 54 duplex ultrasonography 54 desvenlafaxine succinate 54 rindopepimut 54 ULORIC 54 mTOR inhibitors 54 longitudinal observational study 54 conjugated equine estrogen 54 lexidronam injection 54 IFN alfa 54 Multicenter 54 icatibant 54 GOUT 54 pharmacokinetic PK 54 Antiangiogenic 54 reslizumab 54 cytokine refractory 54 ARIXTRA 54 insulin glulisine 54 Phase #b/#a clinical 54 Vectibix panitumumab 54 ADVANCE PD 54 selective androgen receptor modulator 54 randomized Phase III 54 microtubule inhibitor 54 antidiabetic drug 54 Pharmacokinetic studies 54 antiretroviral naïve 54 Phase IIA 54 SANTE 54 PRADAXA 54 Digital Mammographic Imaging 54 nonrandomized 54 CLL SLL 54 Panzem R NCD 54 HORIZONS AMI trial 54 Nebulized 54 Glycopyrrolate 54 Ziprasidone 54 EVEREST II 54 CRLX# 54 chronic idiopathic thrombocytopenic purpura 54 teriparatide 54 Cancidas 54 cisplatin gemcitabine 54 Catheter Associated 54 Candesartan 54 randomized controlled Phase 54 BENICAR HCT 54 radiographic outcomes 54 trodusquemine 54 Surgical Treatment 54 medroxyprogesterone acetate 54 Meets Primary Endpoint 54 PhG alpha 1 54 CALERIE 54 Prostate Lung Colorectal 54 CINQUIL 54 AZILECT ® 54 Eluting Stent 54 randomized crossover 54 Pharmacokinetic parameters 54 Pitavastatin 54 Polyp Prevention Trial 54 GW# [003] 54 Decompensated Heart Failure 54 EGS# 54 MIST II 54 Pharmacodynamics 54 Galectin 3 54 pharmacokinetic parameters 54 Relapsing Multiple Sclerosis 54 evaluating tivozanib 54 factor Xa inhibitor 54 Phase III randomized controlled 54 GEM OS1 54 indibulin 54 Dasatinib 54 thromboprophylaxis 54 ACCOMPLISH 54 mg/m2 cohort 54 pharmacodynamics PD 54 Interferon beta 54 ara C 54 receptor tyrosine kinase inhibitor 54 SE5 OH containing 54 nucleotide analog 54 immunomodulatory therapies 54 Lubiprostone 54 relapsed myeloma 54 administered subcutaneously 54 goserelin 54 INITIATE 54 PEGylated interferon 54 Hydroxyurea 54 salmeterol fluticasone 54 Phase 1b trial 54 ADAGIO study 54 O PPDS 54 Zorbtive TM 54 ExTRACT TIMI 54 CA9 SCAN 54 octreotide acetate 54 antiviral efficacy 54 Liposomal 54 QTcF 54 Preclinical Study 54 Vidofludimus 54 Mg Usa 54 CIMZIA R 54 tipranavir 54 ENDEAVOR III 54 intratympanic 54 pregabalin Lyrica 54 octreotide LAR 54 Left Ventricular Dysfunction 54 Secondary efficacy endpoints 54 photoprotective drug 54 immunomodulatory therapy 54 PRE SURGE 54 LT NS# 54 volociximab 54 Microalbuminuria 54 Phase IIIb 54 PREOS R 54 tacrolimus ointment 54 LAB CGRP 54 Carotid Artery Stenting 54 Phase #b/#a 54 ZYTIGA 54 Platinol ® cisplatin 54 SPRYCEL ® 54 Daclizumab 54 Uterine Cancer 54 QLT# 54 ONTARGET R 54 WHIMS 54 ASSERT 54 RELOVAIR ™ 54 randomized discontinuation 54 uricase 54 Shows Promising 54 treatment naïve genotype 54 galiximab 54 Active Ulcerative Colitis 54 TMC# C# 54 Omacetaxine 54 HOXB# 54 Dose Ranging Study 54 quadrivalent HPV vaccine 54 AVERROES 54 Intervention Effectiveness CATIE 54 antiproliferative effects 54 eprotirome 54 pyridostigmine 54 Serdolect ® 54 TRANSFORMS 54 pramlintide metreleptin combination 54 Bendamustine 54 IL# PE#QQR 54 humanized monoclonal 54 MYTHOS trial 54 Melphalan 54 Irinotecan 54 Calcium Acetate 54 Arimidex Tamoxifen Alone 54 Modrenal 54 MGd 54 caspofungin 54 SNT MC# 54 Synthetic Peptide 54 antiapoptotic 54 novel histone deacetylase 54 laparoscopic radical nephrectomy 54 Kinase Inhibitor 54 Vascular Wrap 54 cardiac repolarization 54 mitoxantrone plus 53 Anti Tumor 53 LHRH receptor positive 53 brivaracetam 53 Arranon 53 bevacizumab Avastin ® 53 Recombinant Human 53 Symadex 53 Immunomodulatory 53 Beta catenin pathway 53 stage IIIb IV 53 HYLENEX recombinant 53 PROTEGE 53 PROCHYMAL 53 NOX E# 53 mg subcutaneous 53 GnRH antagonist 53 chemotherapeutic regimen 53 carboplatin paclitaxel 53 CLL8 53 NFV 53 Ophena 53 Thrombin 53 Angiographic 53 Edoxaban 53 Diabetic Foot Ulcer 53 Randomized Clinical Trial 53 prospective multicenter study 53 Fc fusion protein 53 Phase 2b Clinical Trial 53 multicenter randomized placebo controlled 53 FIX HF 5 53 anti CD3 53 #I TM# 53 efalizumab 53 COPAXONE R 53 Aliskiren 53 Antiviral Therapy 53 multicenter Phase 53 multicenter clinical 53 neo adjuvant 53 symptomatic VTE 53 PSN# [001] 53 multicentre 53 Endurant 53 ABC/3TC 53 phase IIa clinical 53 prospective observational studies 53 Ablation System 53 ascending dose 53 PD LID 53 Panzem NCD 53 pharmacodynamic profile 53 Natalizumab 53 HGS# 53 Cloretazine 53 #:# randomization 53 Phase Ib IIa 53 controlled multicenter Phase 53 Efficacy Trial 53 NO# [002] 53 serotonin norepinephrine reuptake inhibitor 53 relapsing remitting MS RRMS 53 Pegylated Interferon 53 samalizumab 53 metaanalysis 53 trastuzumab Herceptin ® 53 Pyridorin 53 STENT 53 ACE Inhibitor 53 Raloxifene Evaluation MORE 53 Initiates Enrollment 53 GetGoal Phase III 53 SABCS 53 Clinical Efficacy 53 Dual Opioid 53 melphalan prednisone 53 randomizing patients 53 Investigator Initiated 53 Phase III randomized 53 PEG IFN 53 Tyrima 53 mixed hyperlipidemia 53 Meta Analysis 53 Tykerb lapatinib 53 Long Lesion 53 Vinorelbine 53 Embolic Protection Device 53 histamine dihydrochloride 53 Cholesterol Levels SPARCL 53 Aplidin R 53 Carotid endarterectomy 53 finasteride Proscar 53 Vidaza azacitidine 53 oxaliplatin Eloxatin 53 mesilate 53 subcutaneous SC 53 clinical pharmacology studies 53 MEND CABG 53 efavirenz EFV 53 MADIT II 53 AIM HIGH 53 adenosine injection 53 bacillus Calmette Guerin 53 ximelagatran 53 AZOR 53 OVATURE 53 Liraglutide Effect 53 CYT# QbG# 53 Osteopontin 53 GRN# 53 GORE TAG Device 53 ACZ# 53 Enzyme Replacement Therapy 53 metastatic pancreatic 53 flutamide 53 abiraterone acetate 53 Folfox 53 selective phosphodiesterase 53 venous thromboembolic disease 53 doxorubicin cyclophosphamide 53 fallopian tube cancers 53 Corticosteroid 53 Kahalalide F 53 Sustained Efficacy 53 CANCIDAS 53 solithromycin 53 oral salmon calcitonin 53 standard chemotherapy regimen 53 lenalidomide Revlimid 53 RE LY trial 53 MOVIPREP R 53 rFIXFc 53 pretreatment serum 53 relapsing multiple sclerosis 53 resectable pancreatic cancer 53 AFRS TM 53 Triapine 53 multicenter Phase III 53 SUCCEED trial 53 antiepileptic drug 53 Aggressive Reduction 53 tipranavir r 53 Phase 2b kidney transplant 53 EndoTAG TM -1 53 CCX# B 53 Interferon Alfa 53 mGluR2 NAM 53 5 fluorouracil leucovorin 53 placebo controlled Phase III 53 Immunosuppressant 53 Rosuvastatin 53 HCV RESPOND 2 53 tenofovir FTC 53 Moxifloxacin 53 TAXOTERE R 53 Severe Sepsis 53 AVADO 53 tolerability pharmacokinetics 53 pharmacokinetic characteristics 53 NeoRecormon 53 GEM OS2 53 Multicenter Automatic Defibrillator Implantation 53 Mimetics 53 novel VDA molecule 53 PDE4 inhibitor 53 dose dependently 53 Subgroup analysis 53 Placebo controlled 53 Glybera R 53 Aplidin 53 Betaferon ® 53 phase IIb study 53 TroVax ® 53 Meta analyzes 53 ® pioglitazone HCl 53 Epithelial Cell 53 pomalidomide 53 CYP#D# inhibitor 53 midstage clinical 53 phase IIb trial 53 ACUITY trial 53 BEZ# 53 cyclic peptide 53 LCP AtorFen 53 OMP #M# 53 BLP# Liposome Vaccine 53 taxane resistant 53 mapatumumab 53 naltrexone SR 53 PROMACTA 53 topically administered 53 GRNVAC1 53 Observational Study 53 differential gene expression 53 Trobalt 53 corticosteroid dose 53 Sorafenib HCC Assessment 53 sirolimus eluting 53 immunotherapeutic vaccine 53 RRMS patients 53 Lysteda 53 atorvastatin #mg 53 stellate ganglion block 53 nonnucleoside reverse transcriptase inhibitors 53 oral treprostinil 53 XIENCE V Everolimus Eluting 53 CaPSURE 53 omalizumab Xolair 53 subcutaneous methylnaltrexone 53 Proellex TM 53 Levaquin levofloxacin 53 RELIANT 53 Vorapaxar 53 Genzyme Synvisc 53 FOLFOX6 chemotherapy regimen 53 Chronic Heart Failure 53 Zarnestra 53 longitudinal cohort study 53 Bayer HealthCare Onyx Pharmaceuticals 53 GLPG# 53 Pafuramidine 53 placebo controlled studies 53 demonstrated antitumor activity 53 Investigational Treatment 53 Lucanix 53 INTEGRILIN 53 Montelukast 53 Meridia sibutramine 53 HepDirect prodrug 53 CAPRIE 53 #-# Full Text 53 headache nasopharyngitis 53 rFVIIa 53 hepatic arterial 53 REALITY Trial 53 albiglutide 53 Alvesco R 53 ASCO GU 53 nab paclitaxel 53 Ontak 53 fluvastatin 53 Carotid 53 mucosal healing 53 Lantus insulin 53 Initiates Phase III 53 Forodesine HCl 53 Fluorouracil 53 Phase III ThermoDox 53 Aryplase 53 xanthine oxidase inhibitor 53 multicenter placebo controlled 53 Elitek 53 valsartan Diovan 53 aplindore 53 CURRENT OASIS 7 53 hematologic parameters 53 Acute Decompensated Heart Failure 53 tropism testing 53 Phase Ib IIa clinical 53 Spheramine 52 multicenter randomized Phase 52 BioMatrix 52 orally administered inhibitor 52 pharmacokinetic PK profile 52 DIRECT Trial 52 EmbraceAC 52 FOR FURTHER INFORMATION ABOUT 52 ziprasidone 52 Metabolic Efficiency 52 biliary tract cancer 52 inhaled AAT 52 dose dose escalation 52 sirolimus eluting stents 52 Vascugel R 52 orally inhaled 52 Epoetin Alfa 52 BR.# 52 KRN# 52 TASKi2 52 Initiates Clinical 52 tenofovir emtricitabine 52 CCR5 receptor antagonist 52 potent suppressor 52 TAXUS VI 52 Stenting Trial 52 protein tyrosine phosphatase 1B 52 Squalamine 52 placebo controlled multicenter 52 phase IIb clinical 52 intravenous dosing 52 radiolabeled TM# 52 highly selective inhibitor 52 cis retinoic acid 52 antitumor effect 52 Augment Injectable 52 ABCSG 52 BRAF inhibitor 52 Pivotal Phase II 52 Ovarian PLCO Cancer 52 ritonavir boosted atazanavir 52 subcutaneously administered 52 NABTT 52 APEX AMI trial 52 Postdoctoral Position 52 Ceplene/IL-2 52 imatinib therapy 52 Prospective Randomized Trial 52 Dyloject TM 52 PDE# inhibitors 52 AIR CF3 52 #mg BID [001] 52 Psoriasis Drug 52 anti Parkinsonian 52 Cytogenetic 52 agalsidase alfa 52 balsalazide tablet 52 Adult Stem Cell Therapy 52 CLORETAZINE TM VNP#M 52 idraparinux 52 Fulvestrant 52 FAMPYRA 52 OMS# 52 inhaled iloprost 52 CorVue ™ 52 colorectal adenocarcinoma 52 PPAR gamma agonist 52 orally inhaled migraine 52 BEXXAR 52 MEND CABG II 52 MYDICAR ® 52 pravastatin Pravachol 52 mTOR mammalian target 52 Phase III psoriasis 52 lacosamide 52 CUSTOM III 52 Starlix